{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T20:17:08Z","timestamp":1791404228484,"version":"4.3.3"},"reference-count":32,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T00:00:00Z","timestamp":1699315200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100024724","name":"Manchester Clinical Research Facility","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100024724","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009250","name":"National Institute for Social Care and Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009250","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.jcf.2023.10.019","type":"journal-article","created":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T04:56:17Z","timestamp":1699592177000},"page":"269-277","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Influence of highly effective modulator therapy on the sputum proteome in cystic fibrosis"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2137-6619","authenticated-orcid":false,"given":"Rosemary E","family":"Maher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6326-4431","authenticated-orcid":false,"given":"Peter J","family":"Barry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Emmott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew M","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijing","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7055-6034","authenticated-orcid":false,"given":"Paul S","family":"McNamara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8837-4928","authenticated-orcid":false,"given":"Jaclyn A","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9008-2502","authenticated-orcid":false,"given":"Robert W","family":"Lord","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jcf.2023.10.019_bib0001","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1165\/rcmb.2006-0082SF","article-title":"University of North Carolina Virtual Lung G. Effective mucus clearance is essential for respiratory health","volume":"35","author":"Randell","year":"2006","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"10290","key":"10.1016\/j.jcf.2023.10.019_bib0002","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1016\/S0140-6736(20)32542-3","article-title":"Cystic fibrosis","volume":"397","author":"Shteinberg","year":"2021","journal-title":"Lancet"},{"issue":"18","key":"10.1016\/j.jcf.2023.10.019_bib0003","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJMoa1105185","article-title":"A CFTR potentiator in patients with cystic fibrosis and the G551D mutation","volume":"365","author":"Ramsey","year":"2011","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jcf.2023.10.019_bib0004","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1056\/NEJMoa1409547","article-title":"Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR","volume":"373","author":"Wainwright","year":"2015","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.jcf.2023.10.019_bib0005","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1056\/NEJMoa1709846","article-title":"Tezacaftor-Ivacaftor in patients with cystic fibrosis homozygous for Phe508del","volume":"377","author":"Taylor-Cousar","year":"2017","journal-title":"N Engl J Med"},{"issue":"10212","key":"10.1016\/j.jcf.2023.10.019_bib0006","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.jcf.2023.10.019_bib0007","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.jcf.2023.10.019_bib0008","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1056\/NEJMoa2100665","article-title":"Triple therapy for cystic fibrosis Phe508del-gating and -residual function genotypes","volume":"385","author":"Barry","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jcf.2023.10.019_bib0009","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01569-2016","article-title":"Proteomic profile of cystic fibrosis sputum cells in adults chronically infected with Pseudomonas aeruginosa","volume":"50","author":"Pattison","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jcf.2023.10.019_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2022.107002","article-title":"The relationship between lung disease severity and the sputum proteome in cystic fibrosis","volume":"204","author":"Maher","year":"2022","journal-title":"Respir Med"},{"issue":"1","key":"10.1016\/j.jcf.2023.10.019_bib0011","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s40168-019-0636-3","article-title":"Neutrophilic proteolysis in the cystic fibrosis lung correlates with a pathogenic microbiome","volume":"7","author":"Quinn","year":"2019","journal-title":"Microbiome"},{"key":"10.1016\/j.jcf.2023.10.019_bib0012","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02153-2022","article-title":"Longitudinal effects of elexacaftor\/tezacaftor\/ivacaftor on sputum viscoelastic properties, airway infection and inflammation in patients with cystic fibrosis","author":"Schaupp","year":"2023","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.jcf.2023.10.019_bib0013","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s12931-020-01341-z","article-title":"Validation of the portable bluetooth(R) air next spirometer in patients with different respiratory diseases","volume":"21","author":"Exarchos","year":"2020","journal-title":"Respir Res"},{"issue":"4","key":"10.1016\/j.jcf.2023.10.019_bib0014","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1177\/1948550617697177","article-title":"Equivalence tests: a practical primer for t tests, correlations, and meta-analyses","volume":"8","author":"Lakens","year":"2017","journal-title":"Soc Psychol Personal Sci"},{"issue":"2","key":"10.1016\/j.jcf.2023.10.019_bib0015","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1136\/thx.2007.077784","article-title":"Multiple-breath inert gas washout and spirometry versus structural lung disease in cystic fibrosis","volume":"63","author":"Gustafsson","year":"2008","journal-title":"Thorax"},{"issue":"6","key":"10.1016\/j.jcf.2023.10.019_bib0016","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/j.jcf.2021.11.003","article-title":"A restructuring of microbiome niche space is associated with Elexacaftor-Tezacaftor-Ivacaftor therapy in the cystic fibrosis lung","volume":"21","author":"Sosinski","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"17","key":"10.1016\/j.jcf.2023.10.019_bib0017","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21176379","article-title":"Airway inflammation and host responses in the era of CFTR modulators","volume":"21","author":"Keown","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"5","key":"10.1016\/j.jcf.2023.10.019_bib0018","first-page":"532","article-title":"Distribution of protectin (CD59), a complement membrane attack inhibitor, in normal human tissues","volume":"65","author":"Meri","year":"1991","journal-title":"Lab Invest"},{"issue":"3","key":"10.1016\/j.jcf.2023.10.019_bib0019","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1080\/00365520701763209","article-title":"Elevated levels of the complement regulator protein CD59 in severe acute pancreatitis","volume":"43","author":"Lindstrom","year":"2008","journal-title":"Scand J Gastroenterol"},{"issue":"4","key":"10.1016\/j.jcf.2023.10.019_bib0020","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1046\/j.1365-3083.2000.00783.x","article-title":"Detection of a soluble form of the complement membrane attack complex inhibitor CD59 in plasma after acute myocardial infarction","volume":"52","author":"Vakeva","year":"2000","journal-title":"Scand J Immunol"},{"key":"10.1016\/j.jcf.2023.10.019_bib0021","doi-asserted-by":"crossref","first-page":"26274","DOI":"10.1038\/srep26274","article-title":"Soluble CD59 is a novel biomarker for the prediction of obstructive chronic lung allograft dysfunction after lung transplantation","volume":"6","author":"Budding","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.jcf.2023.10.019_bib0022","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1146\/annurev-med-042921-123443","article-title":"Club cell secretory protein in lung disease: emerging concepts and potential therapeutics","volume":"74","author":"Martinu","year":"2023","journal-title":"Annu Rev Med"},{"issue":"3","key":"10.1016\/j.jcf.2023.10.019_bib0023","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.jcf.2014.10.002","article-title":"Sputum club cell protein concentration is associated with pulmonary exacerbation in cystic fibrosis","volume":"14","author":"Laguna","year":"2015","journal-title":"J Cyst Fibros"},{"issue":"3","key":"10.1016\/j.jcf.2023.10.019_bib0024","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1183\/09031936.06.00071405","article-title":"Anti-inflammatory cytokines in cystic fibrosis lung disease","volume":"28","author":"Starosta","year":"2006","journal-title":"Eur Respir J"},{"issue":"4","key":"10.1016\/j.jcf.2023.10.019_bib0025","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1124\/pr.110.002733","article-title":"Neutrophil elastase, proteinase 3, and cathepsin G as therapeutic targets in human diseases","volume":"62","author":"Korkmaz","year":"2010","journal-title":"Pharmacol Rev"},{"issue":"3","key":"10.1016\/j.jcf.2023.10.019_bib0026","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1136\/thx.2005.051979","article-title":"Matrix metalloproteinases in destructive pulmonary pathology","volume":"61","author":"Elkington","year":"2006","journal-title":"Thorax"},{"key":"10.1016\/j.jcf.2023.10.019_bib0027","doi-asserted-by":"crossref","DOI":"10.1002\/ppul.26334","article-title":"Elexacaftor\/tezacaftor\/ivacaftor treatment reduces airway inflammation in cystic fibrosis","author":"De Vuyst","year":"2023","journal-title":"Pediatr Pulmonol"},{"issue":"1","key":"10.1016\/j.jcf.2023.10.019_bib0028","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02096-2022","article-title":"Normalisation of circulating neutrophil counts after 12 months of elexacaftor-tezacaftor-ivacaftor in patients with advanced cystic fibrosis","volume":"61","author":"Dhote","year":"2023","journal-title":"Eur Respir J"},{"issue":"8","key":"10.1016\/j.jcf.2023.10.019_bib0029","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1136\/thorax-2022-219943","article-title":"Effect of elexacaftor\/tezacaftor\/ivacaftor on airway and systemic inflammation in cystic fibrosis","volume":"78","author":"Casey","year":"2023","journal-title":"Thorax"},{"key":"10.1016\/j.jcf.2023.10.019_bib0030","article-title":"Impact of elexacaftor-tezacaftor-ivacaftor on bacterial colonization and inflammatory responses in cystic fibrosis","author":"Sheikh","year":"2022","journal-title":"Pediatr Pulmonol"},{"issue":"12","key":"10.1016\/j.jcf.2023.10.019_bib0031","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1164\/rccm.201609-1954OC","article-title":"Restoring cystic fibrosis transmembrane conductance regulator function reduces airway bacteria and inflammation in people with cystic fibrosis and chronic lung infections","volume":"195","author":"Hisert","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.jcf.2023.10.019_bib0032","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.jcf.2022.03.012","article-title":"Effects of ivacaftor on systemic inflammation and the plasma proteome in people with CF and G551D","volume":"21","author":"Hoppe","year":"2022","journal-title":"J Cyst Fibros"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199323016697?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199323016697?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T08:24:23Z","timestamp":1772353463000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199323016697"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S1569199323016697"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2023.10.019","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2023.04.17.23288625","asserted-by":"object"}]},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Influence of highly effective modulator therapy on the sputum proteome in cystic fibrosis","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2023.10.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.","name":"copyright","label":"Copyright"}]}}